PharmaCyte Biotech (PMCB) Form 3 PharmaCyte Biotech / Michael M Abecassis ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Abecassis Michael M

(Last) (First) (Middle)

23046 AVENIDA DE LA CARLOTA

SUITE 600

(Street)

LAGUNA HILLS CA 92653

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/10/2021

3. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,667(1)	D
Common Stock	800(1)	I	By Transplant Consulting LLC

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	07/03/2017	07/03/2022	Common Stock	334(1)	87(2)	D
Stock Option (right to buy)	07/03/2017	07/03/2022	Common Stock	800(1)	87(2)	I	By Transplant Consulting LLC
Stock Option (right to buy)	07/01/2018	07/01/2023	Common Stock	334(1)	102.45(2)	D
Stock Option (right to buy)	07/01/2019	07/01/2024	Common Stock	334(1)	55.5(2)	D
Stock Option (right to buy)	07/01/2020	07/01/2025	Common Stock	334(1)	37.05(2)	D
Stock Option (right to buy)	07/01/2021	06/30/2026	Common Stock	334(1)	16.2(2)	D

Explanation of Responses:

1. The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").

2. The exercise price has been adjusted to reflect the Reverse Split.

	/s/ Michael M. Abecassis	08/20/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.